Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05600946 · ClinicalTrials.gov registry record
Characterization of Dysmorphology in Subjects With Creatine Transporter Deficiency
A clinical trial of Autism Spectrum Disorder and Metabolic Disease, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- Recruiting
- Registry status
- 19
- Enrollment target
- 1
- Study location
NCT05600946: Recruiting study of Autism Spectrum Disorder and Metabolic Disease, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
NCT05600946 is a study of Autism Spectrum Disorder and Metabolic Disease that is actively recruiting participants, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 19 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05600946, a study of Autism Spectrum Disorder and Metabolic Disease, is actively recruiting participants, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- RECRUITING
- Registry status
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Creatine transporter deficiency (CTD) is a genetic disorder that mainly affects the brain in males. CTD causes intellectual disability that can be mild to severe. People with CTD may have seizures and behavioral issues. They may have slow growth and tire easily. CTD may sometimes be confused with autism or other disorders. Better diagnostics are needed. The study team in an NIH study noted that the faces of children with CTD can look similar. For this natural history study, an expert will examine photos of children with CTD. Any shared traits found might help to diagnose CTD. Objective: To look for shared facial features of children with CTD. Eligibility: Males aged 2 to 40 years old with CTD who were in study 17-CH-0020. Design: Some participants in study 17-CH-0020 had pictures taken of their faces. The NIH study team wants to share these photos with a colleague in Canada. This person is an expert at evaluating how genetic disorders affect people s bodies. Participant data collected during the study may also be sent to this expert. This data may include diagnostic images and results from lab tests. Some children did not have their pictures taken during study 17-CH-0020. Parents are asked to take pictures of these children and send them to the study team. These photos can be sent to a secure portal. The photos can also be taken in-person during a clinic visit. The photos may be printed in clinical study journals. But this is not required. Parents will be asked to sign a separate consent before the photos are published....
Primary Outcome
To characterize the dysmorphic features in subjects with CTD
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-10-24 |
| Est. Completion | 2026-09-01 |
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)305 total trials
What NCT05600946 shows while recruiting
NCT05600946 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (86% lower).
The record links to 3 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT05600946 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05600946 about?
NCT05600946 is a clinical study titled "Characterization of Dysmorphology in Subjects With Creatine Transporter Deficiency". Background: Creatine transporter deficiency (CTD) is a genetic disorder that mainly affects the brain in males. CTD causes intellectual disability that can be mild to severe. People with CTD may have seizures and behavioral issues. They may have slow growth and tire easily. CTD may sometimes be con...
What is the current status of trial NCT05600946?
This trial is currently recruiting. The enrollment target is 19 participants. The study started on 2022-10-24. Estimated completion is 2026-09-01.
What conditions does trial NCT05600946 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Metabolic Disease, Cognitive Disorder.
Who is sponsoring clinical trial NCT05600946?
This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05600946 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05600946's enrollment target sits among peer trials
19 203rd of 224 higher than 20 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design
RECRUITING · Early Phase 1
-
Cannabidiol (CBD) in Adults With ASD
RECRUITING · Phase 1
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI